Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2021.8049
Abstract: Importance The initial assessment of pertuzumab use for treatment of metastatic breast cancer by health technology assessment agencies suggested that pertuzumab was not cost-effective. In Ontario, Canada, pertuzumab became funded in November 2013 based on… read more here.
Keywords: cost; cost effectiveness; pertuzumab; trastuzumab ... See more keywords
Pertuzumab study in the neoadjuvant setting for HER2‐positive nonmetastatic breast cancer in Australia (PeRSIA)
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34245
Abstract: The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA—ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the prognosis of patients with early… read more here.
Keywords: neoadjuvant setting; breast cancer; pertuzumab; study ... See more keywords
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.1855
Abstract: PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2‐positive breast cancer. Pertuzumab is currently approved with an initial loading dose of 840 mg, followed by a… read more here.
Keywords: impact dose; pertuzumab; dosing regimens; alternative dosing ... See more keywords
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03852-z
Abstract: PurposeThe phase III MARIANNE study investigated single-agent trastuzumab emtansine (T-DM1) and combination T-DM1 plus pertuzumab as the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Pharmacokinetic properties of T-DM1… read more here.
Keywords: pertuzumab; her2 positive; dm1; breast cancer ... See more keywords
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03871-w
Abstract: PurposeTo characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the… read more here.
Keywords: pertuzumab trastuzumab; patients her2; her2 positive; pertuzumab ... See more keywords
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-021-06145-3
Abstract: Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab plus intravenous pertuzumab and… read more here.
Keywords: her2 positive; pertuzumab; subcutaneous trastuzumab; safety ... See more keywords
Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2021.01.004
Abstract: Amplification of human epidermal growth factor receptor 2 (HER2) occurs in around 25% of breast cancers and has been associated with aggressive disease. Here, we summarize published evidence on efficacy and prolonged responses with trastuzumab… read more here.
Keywords: breast; pertuzumab; trastuzumab; review ... See more keywords
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
Sign Up to like & getrecommendations! Published in 2020 at "Molecular immunology"
DOI: 10.1016/j.molimm.2020.01.009
Abstract: The majority of patients with metastatic breast cancer who are treated with the anti-HER2 monoclonal antibody, trastuzumab, generally develop resistance to the drug within a year after initiation of the treatment. Here we describe a… read more here.
Keywords: combination; pertuzumab; anti her2; antibody ... See more keywords
Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation
Sign Up to like & getrecommendations! Published in 2023 at "Analytical Chemistry"
DOI: 10.1021/acs.analchem.2c03275
Abstract: Pertuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer in combination with trastuzumab. Charge variants of trastuzumab have been extensively described in the literature; however, little is known about the charge… read more here.
Keywords: heavy chain; stress; deamidation; charge ... See more keywords
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001310
Abstract: In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by… read more here.
Keywords: locally advanced; oncology; advanced inflammatory; inflammatory early ... See more keywords
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000911
Abstract: Background HER2 is a therapeutic target for metastatic colorectal cancer (mCRC), as demonstrated in the pivotal HERACLES-A (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification) trial with trastuzumab and lapatinib. The aim of HERACLES-B trial is… read more here.
Keywords: metastatic colorectal; trial; pertuzumab; colorectal cancer ... See more keywords